Latest news and press releases about Boundless Bio, Inc. (BOLD): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers.
Price
| Price | $2.82 |
| Market Cap | $63M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.96 |
| EV / EBITDA | -0.76 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -70.89% |
| Return on Invested Capital | -103.08% |
| Return on Assets | -86.80% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANTX · INTS · ITRM · NXTC · PLUR · PSTV · QTTB
Explore sector: Healthcare · Biotechnology
More sections of BOLD: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks